Literature DB >> 30648199

Prediction of biological characteristics of breast cancer using dual-phase FDG PET/CT.

Shinsuke Sasada1, Norio Masumoto2, Eri Suzuki2, Satoshi Sueoka2, Noriko Goda2, Keiko Kajitani2, Akiko Emi2, Takayuki Kadoya2, Morihito Okada2.   

Abstract

PURPOSE: The aim of this study was to assess whether the retention index (RI) determined using dual-phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) reflects the malignant features of breast cancer.
METHODS: A total of 1,523 patients with breast cancer were retrospectively evaluated. PET/CT scans were performed at 1 h and 2 h after FDG administration before treatment. The maximum standardized uptake value (SUVmax) at both time points (SUVmax1 and SUVmax2) in the primary tumour and RI were calculated. Primary tumour tissues were evaluated in terms of biological features, such as histology, nuclear grade, lymphovascular invasion and molecular subtype.
RESULTS: Of the 1,523 patients, 463 (30.4%) had luminal A-like, 661 (43.4%) had luminal B-like, 229 (15.0%) had human epidermal growth factor receptor 2-positive (HER2-positive), and 157 (10.3%) triple-negative breast cancer. The median SUVmax1, SUVmax2 and RI values were 2.2, 2.3 and 2.6%, respectively. These metabolic parameters were correlated with tumour size, nodal metastasis, histology, nuclear grade, lymphovascular invasion, and molecular subtype (all P < 0.001). The median RI values were 0% in luminal A-like, 5.3% in luminal B-like, 6.9% in HER2-positive, and 11.4% in triple-negative breast cancer. RI was associated with malignant features when the tumour accumulated a significant amount of FDG. In a subanalysis of patients with tumours of stages T2 to T4, RI was correlated with nodal metastasis, histology, nuclear grade, and molecular subtype (luminal A-like 4.8%, luminal B-like 12.3%, HER2-positive 15.8%, and triple-negative 16.3%).
CONCLUSION: RI determined using delayed-phase FDG PET/CT is associated with malignant features in breast cancers with significant FDG uptake. Dual-phase imaging was helpful in distinguishing luminal A-like breast cancer from luminal B-like, HER2-positive, and triple-negative breast cancers.

Entities:  

Keywords:  Breast cancer; Dual-phase; FDG; PET; Retention index

Mesh:

Substances:

Year:  2019        PMID: 30648199     DOI: 10.1007/s00259-019-4259-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  21 in total

Review 1.  Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

Authors:  A Goldhirsch; W C Wood; R D Gelber; A S Coates; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2007-07       Impact factor: 32.976

Review 2.  Partial-volume effect in PET tumor imaging.

Authors:  Marine Soret; Stephen L Bacharach; Irène Buvat
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

3.  18F-FDG retention index and biologic prognostic parameters in breast cancer.

Authors:  Ana María García Vicente; Ángel Soriano Castrejón; Fernanda Relea Calatayud; Azahara Palomar Muñoz; Antonio Alberto León Martín; Ignacio Chacón López-Muñiz; María Del Mar Muñoz Sánchez; José Manuel Cordero García; Edward Mitsuro Becerra Nakayo
Journal:  Clin Nucl Med       Date:  2012-05       Impact factor: 7.794

4.  Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Authors:  David Groheux; Sylvie Giacchetti; Jean-Luc Moretti; Raphael Porcher; Marc Espié; Jacqueline Lehmann-Che; Anne de Roquancourt; Anne-Sophie Hamy; Caroline Cuvier; Laetitia Vercellino; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-06       Impact factor: 9.236

5.  Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer.

Authors:  A R Boerner; M Weckesser; H Herzog; T Schmitz; W Audretsch; U Nitz; H G Bender; H W Mueller-Gaertner
Journal:  Eur J Nucl Med       Date:  1999-03

6.  Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET.

Authors:  Rakesh Kumar; Vilert A Loving; Anil Chauhan; Hongming Zhuang; Schnall Mitchell; Abass Alavi
Journal:  J Nucl Med       Date:  2005-11       Impact factor: 10.057

Review 7.  Why do cancers have high aerobic glycolysis?

Authors:  Robert A Gatenby; Robert J Gillies
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

8.  Cosmetic outcome and patient satisfaction after skin-sparing mastectomy for breast cancer with immediate reconstruction of the breast.

Authors:  Satsuki Ueda; Yasuhiro Tamaki; Kenji Yano; Noritsugu Okishiro; Tetsu Yanagisawa; Mitsunobu Imasato; Kenzo Shimazu; Seun J Kim; Yasuo Miyoshi; Yoshio Tanji; Tetsuya Taguchi; Shinzaburo Noguchi
Journal:  Surgery       Date:  2007-12-21       Impact factor: 3.982

9.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

10.  18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.

Authors:  A M García Vicente; A Soriano Castrejón; F Relea Calatayud; V Muñoz Madero; M J Molina Garrido; A A León Martín; J M Cordero García; J P Pilkington Woll; I Chacón López-Muñiz; A Palomar Muñoz
Journal:  Rev Esp Med Nucl Imagen Mol       Date:  2012-03-19       Impact factor: 1.359

View more
  3 in total

1.  Diagnostic performance of dedicated breast positron emission tomography.

Authors:  Rikako Hashimoto; Sadako Akashi-Tanaka; Chie Watanabe; Hiroko Masuda; Kanae Taruno; Tomoko Takamaru; Yoshimi Ide; Takashi Kuwayama; Yasuhiro Kobayashi; Masafumi Takimoto; Seigo Nakamura
Journal:  Breast Cancer       Date:  2022-06-29       Impact factor: 3.307

2.  Prognostic Value of Metabolic, Volumetric and Textural Parameters of Baseline [18F]FDG PET/CT in Early Triple-Negative Breast Cancer.

Authors:  Clément Bouron; Clara Mathie; Valérie Seegers; Olivier Morel; Pascal Jézéquel; Hamza Lasla; Camille Guillerminet; Sylvie Girault; Marie Lacombe; Avigaelle Sher; Franck Lacoeuille; Anne Patsouris; Aude Testard
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

3.  Super Early Scan of PSMA PET/CT in Evaluating Primary and Metastatic Lesions of Prostate Cancer.

Authors:  Juanli Mao; Mingjun Gao; Bin Cui; Yingying Zhang; Xiaojiao Wang; Siyu Liang; Changjing Zuo; Peng Chen; Aisheng Dong
Journal:  Molecules       Date:  2022-07-21       Impact factor: 4.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.